[Corrigendum] Use of methylation profiling to identify significant differentially methylated genes in bone marrow mesenchymal stromal cells from acute myeloid leukemia.

Following the publication of the above article, an interested reader drew to the authors' and the Editor's attention that, given the subject matter of the article, in a few places in the text throughout the paper, 'MIR159' was probably intended to have been written as 'MIR596', and 'miR‑159' was probably meant to have been written as 'miR‑596'. The authors have responded to confirm that the interested reader was correct in their assessment; this paper discusses the role of miR‑596 in the context of acute myeloid leukemia (AML) and its potential as a biomarker, and this error appears to have occurred during the final stages of manuscript preparation. Therefore, the following corrections to the text of this article should be noted:  a) In the final sentence of the Abstract on p. 679, 'miR‑596' should have been written, rather than 'miR‑159'. The corrected sentence should read as follows: 'Furthermore, the aberrantly hypermethylated ‑encoding gene may be a potential biomarker of AML.' b) In the Discussion, all instances where 'miR‑159' and 'MIR159' were mentioned should be corrected to 'miR‑596' and 'MIR596', respectively. The sentences concerned should have read as follows (p. 685, right‑hand column, line 9): 'Thus, it was suggested that the hypermethylation of may be associated with its transcriptional regulation. It was also inferred that methylation in BM‑MSCs may be a biomarker or prognostic factor for patients with AML. However, the significance of the methylation of miR‑596 demands further investigation." In addition, the sentence starting on p. 685, right‑hand column, second paragraph, line 5, should have read as follows: 'Furthermore, the aberrant hypermethylated ‑encoding gene may be a potential biomarker of AML.' All the authors agree with the publication of this corrigendum; furthermore, they also apologize to the readership of the journal for any inconvenience caused. [International Journal of Molecular Medicine  41: 679‑686, 2018; DOI: 10.3892/ijmm.2017.3271].